Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

The Lancet Oncology

Volumn 9, Issue 5, 2008, Pages 453-461

  Brandsma, Dieta ^a,b   Stalpers, Lukas ^c   Taal, Walter ^a   Sminia, Peter ^d   van den Bent, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBON 11; CERAMIDE; CORTICOSTEROID; DNA; FLUORODEOXYGLUCOSE F 18; METHIONINE; METHOTREXATE; PROTEIN KINASE C; SPHINGOMYELIN PHOSPHODIESTERASE; TEMOZOLOMIDE; VASCULOTROPIN;

ADJUVANT THERAPY; APOPTOSIS; BLOOD VESSEL PERMEABILITY; BRACHYTHERAPY; BRAIN EDEMA; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CELL KILLING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DNA DAMAGE; ENDOTHELIUM CELL; ENZYME ACTIVATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LEUKOENCEPHALOPATHY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION NECROSIS; RECURRENCE RISK; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STEREOTACTIC RADIOSURGERY; SYMPTOM; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN EDEMA; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NECROSIS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42649106522     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70125-6     Document Type: Review

References (75)

1. Walker M., Alexander Jr. E., Hunt W., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 (1978) 333-343
2. Heesters M., Wijrdeman H., Struikmans H., Witkamp T., and Moerland M. Brain tumor delineation based on CT and MR imaging. Implications for radiotherapy treatment planning. Strahlenther Onkol 169 (1993) 729-733
3. Nieder C., Andratschke N., Wiedenmann N., Busch R., Grosu A., and Molls M. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?. Strahlenther Onkol 180 (2004) 401-407
4. Stupp R., Mason W., van den Bent M., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
5. de Wit M., de Bruin H., Eijkenboom W., Smitt P.S., and van den Bent M. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63 (2004) 535-537
6. Chamberlain M., Glantz M., Chalmers L., Van Horn A., and Sloan A. Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82 (2007) 81-83
7. Rades D., Kieckebusch S., Lohynska R., et al. Reduction of overall treatment time in patients irradiated for more than three brain metastases. Int J Radiat Oncol Biol Phys 69 (2007) 1509-1513
8. Rades D., Pluemer A., Veninga T., Hanssens P., Dunst J., and Schild S. Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer 110 (2007) 2285-2292
9. Sheline G., Wara W., and Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6 (1980) 1215-1228
10. Wong C., and van der Kogel A. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4 (2004) 273-284
11. Young D., Posner J., Chu F., and Nisce L. Rapid-course radiation therapy of cerebral metastases: results and complications. Cancer 34 (1974) 1069-1076
12. Kumar A., Leeds N., Fuller G., et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217 (2000) 377-384
13. Belka C., Budach W., Kortmann R., and Bamberg M. Radiation induced CNS toxicity-molecular and cellular mechanisms. Br J Cancer 85 (2001) 1233-1239
14. Fouladi M., Chintagumpala M., Laningham F., et al. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 22 (2004) 4551-4560
15. Johannesen T., Lien H., Hole K., and Lote K. Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy. Radiother Oncol 69 (2003) 169-176
16. Oka M., Terae S., Kobayashi R., et al. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 45 (2003) 493-497
17. Perry A., and Schmidt R. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 111 (2006) 197-212
18. DeAngelis L., and Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 31 (2004) 684-692
19. Blay J., Conroy T., Chevreau C., et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16 (1998) 864-871
20. Abrey L., Yahalom J., and DeAngelis L. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18 (2000) 3144-3150
21. Bleyer W., Fallavollita J., Robison L., et al. Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from the Children's Cancer Study Group. Pediatr Hematol Oncol 7 (1990) 329-338
22. Giglio P., and Gilbert M. Cerebral radiation necrosis. Neurologist 9 (2003) 180-188
23. Marks J., Baglan R., Prassad S., and Blank W. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 7 (1981) 243-252
24. Ruben J., Dally M., Bailey M., Smith R., McLean C., and Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 499-508
25. Gonzalez D., Menten J., Bosch D., et al. Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study. Radiother Oncol 32 (1994) 98-105
26. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
27. Hertzberg H., Huk W., Ueberall M., et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL-an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 28 (1997) 387-400
28. Mulhern R., Merchant T., Gajjar A., Reddick W., and Kun L. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5 (2004) 399-408
29. Floyd N., Woo S., Teh B., et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 58 (2004) 721-726
30. McDermott M., Sneed P., and Gutin P. Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 14 (1998) 79-87
31. Bauman G., Sneed P., Wara W., et al. Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 36 (1996) 433-441
32. Mayer R., and Sminia P. Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70 (2008) 1350-1360
33. Soffietti R., Sciolla R., Giordana M., Vasario E., and Schiffer D. Delayed adverse effects after irradiation of gliomas: clinicopathological analysis. J Neurooncol 3 (1985) 187-192
34. Rubinstein J., Herman M., Long T., and Wilbur J. Leukoencephalopathy following combined therapy of central nervous system leukemia and lymphoma. Acta Neuropathol Suppl 6 suppl (1975) 251-255
35. Taal W., Brandsma D., de Bruin H., et al. The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide. Proc Am Soc Clin Oncol 25 (2007) (abstr 2009).
36. Brandes A., Tosini A., Franceschi E., et al. Pseudoprogression after concomitant radio-chemotherapy treatment in newly diagnosed glioblastoma patients and potential correlation with MGMT methylations status. http://neuro-oncology.dukejournals.org/cgi/reprint/9/4/467.pdf (accessed April 2, 2008).
37. Moody D., Bell M., and Challa V. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol 11 (1990) 431-439
38. Lee A., Foo W., Chappell R., et al. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 40 (1998) 35-42
39. Berger P., and Bataini J. Radiation-induced cranial nerve palsy. Cancer 40 (1977) 152-155
40. Parsons J., Bova F., Fitzgerald C., Mendenhall W., and Million R. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 30 (1994) 755-763
41. Hudgins P., Newman N., Dillon W., and Hoffman Jr. J. Radiation-induced optic neuropathy: characteristic appearances on gadolinium-enhanced MR. AJNR Am J Neuroradiol 13 (1992) 235-238
42. Fiegler W., Langer M., Scheer M., and Kazner E. [Reversible computed tomographic changes following brain tumor irradiation induced by the "early-delayed reaction" after radiation]. Radiologe 26 (1986) 206-209
43. Watne K., Hager B., Heier M., and Hirschberg H. Reversible oedema and necrosis after irradiation of the brain. Diagnostic procedures and clinical manifestations. Acta Oncol 29 (1990) 891-895
44. Griebel M., Friedman H., Halperin E., et al. Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. Med Pediatr Oncol 19 (1991) 182-186
45. Packer R., Zimmerman R., Kaplan A., et al. Early cystic/necrotic changes after hyperfractionated radiation therapy in children with brain stem gliomas. Data from the Childrens Cancer Group. Cancer 71 (1993) 2666-2674
46. Kleinschmidt-DeMasters B., and Geier J. Pathology of high-dose intraarterial BCNU. Surg Neurol 31 (1989) 435-443
47. O'Connor M., and Mayberg M. Effects of radiation on cerebral vasculature: a review. Neurosurgery 46 (2000) 138-149
48. Danson S., and Middleton M. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 1 (2001) 13-19
49. Chakravarti A., Erkkinen M., Nestler U., et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12 (2006) 4738-4746
50. Hegi M., Diserens A., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
51. Tofilon P., and Fike J. The radioresponse of the central nervous system: a dynamic process. Radiat Res 153 (2000) 357-370
52. Fajardo L., Bathrong M., and Anderson R. Radiation pathology (2001), Oxford University Press, New York
53. Brown W., Thore C., Moody D., Robbins M., and Wheeler K. Vascular damage after fractionated whole-brain irradiation in rats. Radiat Res 164 (2005) 662-668
54. Brown W., Blair R., Moody D., et al. Capillary loss precedes the cognitive impairment induced by fractionated whole-brain irradiation: a potential rat model of vascular dementia. J Neurol Sci 257 (2007) 67-71
55. Verheij M., Dewit L., Boomgaard M., Brinkman H., and van Mourik J. Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor. Radiat Res 137 (1994) 202-207
56. Quarmby S., Kumar P., and Kumar S. Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. Int J Cancer 82 (1999) 385-395
57. Nordal R., Nagy A., Pintilie M., and Wong C. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 10 (2004) 3342-3353
58. Gupta V., Jaskowiak N., Beckett M., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8 (2002) 47-54
59. Rodemann H., and Blaese M. Responses of normal cells to ionizing radiation. Semin Radiat Oncol 17 (2007) 81-88
60. Lin T., Genestier L., Pinkoski M., et al. Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. J Biol Chem 275 (2000) 8657-8663
61. Liao W., Haimovitz-Friedman A., Persaud R., et al. Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem 274 (1999) 17908-17917
62. Miyashita T., Krajewski S., Krajewska M., et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
63. Li Y., Chen P., Haimovitz-Friedman A., Reilly R., and Wong C. Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer Res 63 (2003) 5950-5956
64. Tan J., Geng L., Yazlovitskaya E., and Hallahan D. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiated vascular endothelium. Cancer Res 66 (2006) 2320-2327
65. Haimovitz-Friedman A., Balaban N., McLoughlin M., et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54 (1994) 2591-2597
66. Fuks Z., Persaud R., Alfieri A., et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54 (1994) 2582-2590
67. Rock J., Scarpace L., Hearshen D., et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54 (2004) 1111-1117
68. Chan Y., Yeung D., Leung S., and Chan P. Diffusion-weighted magnetic resonance imaging in radiation-induced cerebral necrosis. Apparent diffusion coefficient in lesion components. J Comput Assist Tomogr 27 (2003) 674-680
69. Hein P., Eskey C., Dunn J., and Hug E. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25 (2004) 201-209
70. Zeng Q., Li C., Liu H., Zhen J., and Feng D. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 68 (2007) 151-158
71. Ricci P., Karis J., Heiserman J., Fram E., Bice A., and Drayer B. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 19 (1998) 407-413
72. Tsuyuguchi N., Takami T., Sunada I., et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma. Ann Nucl Med 18 (2004) 291-296
73. Rachinger W., Goetz C., Popperl G., et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57 (2005) 505-511
74. Woo E., Lam K., Yu Y., Lee P., and Huang C. Cerebral radionecrosis: is surgery necessary?. J Neurol Neurosurg Psychiatry 50 (1987) 1407-1414
75. Gonzalez J., Kumar A., Conrad C., and Levin V. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67 (2007) 323-326